Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DBV Technologies (DBVT) Current Deferred Revenue (2015 - 2018)

DBV Technologies (DBVT) reported Current Deferred Revenue of $5.0 million for Q4 2018, up 51.54% year-over-year from $3.3 million in Q4 2017, and up 51.54% on a QoQ basis from $3.3 million in Q4 2017.

DBV Technologies (DBVT) has 4 years of Current Deferred Revenue data on file, last reported at $5.0 million in Q4 2018.

  • Quarterly Current Deferred Revenue rose 51.54% year-over-year to $5.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $5.0 million (up 51.54% YoY) and the FY2018 annual result came in at $5.0 million, up 51.54% from the prior year.
  • Current Deferred Revenue advanced to $5.0 million in Q4 2018 per DBVT's latest filing, from $3.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $5.0 million in Q4 2018 and bottomed at $867028.8 in Q4 2015.
  • The 4-year median for Current Deferred Revenue is $3.4 million (2016), against an average of $3.2 million.
  • The widest annual swing landed in 2016, when Current Deferred Revenue surged 304.48%; it then retreated 6.36% in 2017.
  • Tracing DBVT's Current Deferred Revenue over 4 years: stood at $867028.8 in 2015, then surged by 304.48% to $3.5 million in 2016, then slipped by 6.36% to $3.3 million in 2017, then soared by 51.54% to $5.0 million in 2018.
  • Per Business Quant, the three latest DBVT Current Deferred Revenue figures stand at $5.0 million (Q4 2018), $3.3 million (Q4 2017), and $3.5 million (Q4 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 4.98 Mn
Dec 31, 2017 3.28 Mn
Dec 31, 2016 3.51 Mn
Dec 31, 2015 867,028.77